Expand All

Representative Matters

  • Representation of an international pharmaceutical company and leader in the generics industry in connection with the acquisition of worldwide rights to a therapeutic treatment for metastatic prostate cancer.
  • Representation of a publicly-traded pharmaceutical company in the purchase of a business focused on marketing and sale of branded pharmaceuticals, including a lead product detailed primarily to endocrinologists and high prescribing primary care physicians.
  • Representation of an Italian multinational company and global in vitro diagnostics leader in the acquisition of the Focus Diagnostics’ immunodiagnostic and molecular diagnostic products business from Quest Diagnostics (NYSE:DGX) for $300 million.
  • Representation of the owner/operator of integrated senior health care campuses in several states in the $1.25 billion sale of its health care facility portfolio to a joint venture comprised of two publicly traded REITs.
  • Representation of a pharmaceutical company in the acquisition of the rights to three branded women’s health products from Upsher-Smith Laboratories, Inc.
  • Representation of a health care fund in an investment in Aeglea Biotherapeutics, Inc.
  • Representation of a health care technology company in the sale of substantially all the assets of its pharmaceutical chemistry development and manufacturing business to a subsidiary of McKesson Corporation.
  • Representation of a company developing products to diagnose and treat dry and wet age-related macular degeneration (AMD) and other chronic diseases involving the alternative complement system in its start-up financing.
  • Representation of a developer, manufacturer and marketer of pharmaceutical products in the sale of its generic prescription caffeine suppository used for the treatment of migraines, to Crealta Pharmaceuticals LLC, a specialty pharma company formed by GTCR, a leading private equity firm.
  • Representation of a biotechnology company in an exclusive worldwide license agreement with Bayer AS for the development and commercialization of therapeutic antibodies containing the company’s prostate specific membrane antigen (PSMA) antibody technology.
  • Representation of a bone reconstruction company in its spin-out from Columbia University, and its Series A Convertible Note Financing and exclusive worldwide license agreement with Columbia Technology Ventures.
  • Representation of a biotechnology company in an exclusive worldwide license agreement with Johns Hopkins University for 18F DCFPyL.
  • Representation of new venture capital-backed companies in their organization and the licensing of platform technology from Yale University, Columbia University and other universities.

In the News



Client Alerts

Practice Members